...
mreo-img

Mereo BioPharma Group PLC ADR, Common Stock

MREO

NAQ

$3.85

-$0.01

(-0.26%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$630.80M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
649.67K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.97
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.97 L
$5.02 H
$3.85

About Mereo BioPharma Group PLC ADR, Common Stock

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMREOSectorS&P500
1-Week Return8.15%-1.8%-0.77%
1-Month Return-10.05%-3.48%0.71%
3-Month Return-17.38%-7.2%8.81%
6-Month Return9.38%-1.54%12.32%
1-Year Return93.47%8.39%30.57%
3-Year Return134.76%6.07%29.21%
5-Year Return126.87%44.07%91.95%
10-Year Return-40.77%106.3%196.04%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue(122.00K)393.00K36.46M1.51M10.00M[{"date":"2019-12-31","value":-0.33,"profit":false},{"date":"2020-12-31","value":1.08,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":4.13,"profit":true},{"date":"2023-12-31","value":27.42,"profit":true}]
Cost of Revenue23.61M16.35M17.91M936.00K2.57M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":69.24,"profit":true},{"date":"2021-12-31","value":75.86,"profit":true},{"date":"2022-12-31","value":3.96,"profit":true},{"date":"2023-12-31","value":10.9,"profit":true}]
Gross Profit(23.73M)(15.95M)18.56M571.00K7.43M[{"date":"2019-12-31","value":-127.88,"profit":false},{"date":"2020-12-31","value":-85.98,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":3.08,"profit":true},{"date":"2023-12-31","value":40.02,"profit":true}]
Gross Margin19450.82%(4059.54%)50.89%37.89%74.26%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-20.87,"profit":false},{"date":"2021-12-31","value":0.26,"profit":true},{"date":"2022-12-31","value":0.19,"profit":true},{"date":"2023-12-31","value":0.38,"profit":true}]
Operating Expenses15.91M21.22M39.49M44.51M35.84M[{"date":"2019-12-31","value":35.75,"profit":true},{"date":"2020-12-31","value":47.68,"profit":true},{"date":"2021-12-31","value":88.74,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.53,"profit":true}]
Operating Income(39.52M)(37.57M)(20.94M)(43.57M)(28.42M)[{"date":"2019-12-31","value":-3951700000,"profit":false},{"date":"2020-12-31","value":-3756900000,"profit":false},{"date":"2021-12-31","value":-2093600000,"profit":false},{"date":"2022-12-31","value":-4356900000,"profit":false},{"date":"2023-12-31","value":-2841600000,"profit":false}]
Total Non-Operating Income/Expense(5.18M)(135.61M)36.14M4.81M(2.33M)[{"date":"2019-12-31","value":-14.32,"profit":false},{"date":"2020-12-31","value":-375.29,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":13.31,"profit":true},{"date":"2023-12-31","value":-6.45,"profit":false}]
Pre-Tax Income(41.12M)(166.45M)14.24M(36.09M)(30.00M)[{"date":"2019-12-31","value":-288.73,"profit":false},{"date":"2020-12-31","value":-1168.81,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-253.44,"profit":false},{"date":"2023-12-31","value":-210.65,"profit":false}]
Income Taxes(6.27M)(2.82M)1.52M(1.90M)(532.00K)[{"date":"2019-12-31","value":-413.85,"profit":false},{"date":"2020-12-31","value":-186.15,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-125.13,"profit":false},{"date":"2023-12-31","value":-35.09,"profit":false}]
Income After Taxes(34.84M)(163.63M)12.72M(34.20M)(29.47M)[{"date":"2019-12-31","value":-273.82,"profit":false},{"date":"2020-12-31","value":-1285.88,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-268.73,"profit":false},{"date":"2023-12-31","value":-231.56,"profit":false}]
Income From Continuous Operations(34.84M)(163.63M)12.72M(34.20M)(29.47M)[{"date":"2019-12-31","value":-273.82,"profit":false},{"date":"2020-12-31","value":-1285.88,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-268.73,"profit":false},{"date":"2023-12-31","value":-231.56,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(34.84M)(163.63M)12.72M(34.20M)(29.47M)[{"date":"2019-12-31","value":-273.82,"profit":false},{"date":"2020-12-31","value":-1285.88,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-268.73,"profit":false},{"date":"2023-12-31","value":-231.56,"profit":false}]
EPS (Diluted)(5.12)(3.66)-(0.16)-[{"date":"2019-12-31","value":-511.79,"profit":false},{"date":"2020-12-31","value":-365.63,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-15.93,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MREO
Cash Ratio 5.67
Current Ratio 6.10

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MREO
ROA (LTM) -23.86%
ROE (LTM) -48.47%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MREO
Debt Ratio Lower is generally better. Negative is bad. 0.18
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.82

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MREO
Trailing PE NM
Forward PE NM
P/S (TTM) 598.86
P/B 8.13
Price/FCF NM
EV/R 515.71
EV/Ebitda NM

FAQs

What is Mereo BioPharma Group PLC ADR share price today?

Mereo BioPharma Group PLC ADR (MREO) share price today is $3.85

Can Indians buy Mereo BioPharma Group PLC ADR shares?

Yes, Indians can buy shares of Mereo BioPharma Group PLC ADR (MREO) on Vested. To buy Mereo BioPharma Group PLC ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MREO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Mereo BioPharma Group PLC ADR be purchased?

Yes, you can purchase fractional shares of Mereo BioPharma Group PLC ADR (MREO) via the Vested app. You can start investing in Mereo BioPharma Group PLC ADR (MREO) with a minimum investment of $1.

How to invest in Mereo BioPharma Group PLC ADR shares from India?

You can invest in shares of Mereo BioPharma Group PLC ADR (MREO) via Vested in three simple steps:

  • Click on Sign Up or Invest in MREO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Mereo BioPharma Group PLC ADR shares
What is Mereo BioPharma Group PLC ADR 52-week high and low stock price?

The 52-week high price of Mereo BioPharma Group PLC ADR (MREO) is $5.02. The 52-week low price of Mereo BioPharma Group PLC ADR (MREO) is $1.97.

What is Mereo BioPharma Group PLC ADR price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Mereo BioPharma Group PLC ADR (MREO) is

What is Mereo BioPharma Group PLC ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Mereo BioPharma Group PLC ADR (MREO) is 8.13

What is Mereo BioPharma Group PLC ADR dividend yield?

The dividend yield of Mereo BioPharma Group PLC ADR (MREO) is 0.00%

What is the Market Cap of Mereo BioPharma Group PLC ADR?

The market capitalization of Mereo BioPharma Group PLC ADR (MREO) is $630.80M

What is Mereo BioPharma Group PLC ADR’s stock symbol?

The stock symbol (or ticker) of Mereo BioPharma Group PLC ADR is MREO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top